Where Will Moderna Be in 1 Year?

According to the World Health Organization, there are more than 150 novel coronavirus vaccine candidates in development now, with nearly 30 of them in clinical testing. U.S.-based Moderna (NASDAQ:MRNA) reported positive results from the phase 1 trial for its COVID-19 mRNA vaccine in July, and started the phase 3 trial on July 27. It's no surprise that its stock is up 245% year to date, while the S&P 500 has risen just 9%.

But what will happen to Moderna if its late-stage trials aren't successful, or if regulatory approvals for its potential vaccine pose some challenge? Even if it is successful, what does the next year look like for the company?